RALEIGH — Kineticos Ventures, the investment arm of the Kineticos Life Sciences consulting firm, had a busy August. According to the SEC, the group has raised more than $23 million across two funds.

On Aug. 31 the Kineticos Disruptor Fund disclosed $10.65 million in equity funding from 11 investors. The fund also raised money in May of this year, collecting more than $10 million from 2 equity investors according to that filing. Previous Disruptor Funds have collected more than $55 million in investments.

Kineticos staff were also listed on the SEC filing for the Kineticos AMR Accelerator Fund, which came out on August 10. That filing disclosed more than $12.5 million raised from 15 investors, with a total target of $20 million for the fund. The Kineticos Ventures site notes with concern the global increase in Antimicrobial Resistance (AMR) over the past few decades.

Cell therapies manufacturing startup with big RTP presence raises $30M

Kineticos Ventures has been busy investing as well. In late May, eXmoor pharma, a UK cell and gene therapy manufacturer partner closed on a $35 million Series A round of funding from Kineticos and one other.

In late July Kincell Bio announced its launch with $36 million in funding led by Kineticos. Kincell was spun out of Inceptor Bio of Morrisville, also in the Kineticos portfolio. Shailesh Maingi, the Kineticos Ventures Founder and chairman of the Board is also the founder of Inceptor Bio, and Chairman of the Board for Kincell Bio. The Kineticos Venture portfolio also includes 7 other biotech companies.

According to press releases, Kineticos Ventures’ portfolio of investments is “striving to disrupt how drugs are developed, diseases are diagnosed, and patients are treated.”

Kineticos Life Sciences, LLC was started in 2012, with Kineticos Ventures, LLC starting up in 2021.